Overview

A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT

Status:
NOT_YET_RECRUITING
Trial end date:
2029-11-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, open-label, randomized trial designed to evaluate the DFS of TURBT followed by NDV-1 (sustained-release gemcitabine-docetaxel) versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
Phase:
PHASE3
Details
Lead Sponsor:
Relmada Therapeutics, Inc.